Validation of immune function testing during a 4-week oral toxicity study with FK506

Area of Science:

• Immunotoxicology
• Pharmacology
• Regulatory Science

Background:

• European guidelines mandate immune response assessment in drug toxicity testing.
• Evaluating antibody generation under drug influence is critical for safety.

Purpose of the Study:

• To validate a method for determining Keyhole Limpet Haemocyanin (KLH)-specific antibodies in rats exposed to an immunosuppressant.
• To assess the impact of FK506 on the immune system's antibody production capacity.

Main Methods:

• Rats received oral FK506 (0.5 or 3 mg/kg/day) for 4 weeks.
• Keyhole Limpet Haemocyanin (KLH) was administered subcutaneously on days 14 and 22.
• Antibody titers (IgG, IgM) were measured via ELISA; spleen/thymus weights, immunophenotyping (FACS), and histopathology were assessed.

Main Results:

• FK506 (3 mg/kg) reduced KLH-induced granuloma and germinal center development.
• Suppressed KLH-specific antibody production (IgG, IgM) was observed.
• Reduced CD4+ T-cell counts and lymphopenia were noted at 3 mg/kg, consistent with FK506's known effects.

Conclusions:

• Determining antibody titers after KLH immunization during drug exposure is a valid immunotoxicity evaluation method.
• This validated method supports regulatory requirements for repeated dose toxicity testing.
• The study confirms FK506's immunosuppressive activity in rats.